Newark, New Jersey 07101

  • Pancreatic Cancer


Safety study to determine highest dose of 90Y-hPAM4 can be safety administered

Study summary:

radiolabeled anti-MUC1 humanized antibody) administered intravenously as a single dose to patients with locally advanced and/or metastatic pancreatic cancer. The primary objective is to determine the dose-limiting toxicity (DLT) and maximum tolerated dose (MTD) of 90Y-hPAM4 in this population. Secondary objectives include the assessment of tumor targeting, biodistribution, organ dosimetry and pharmacokinetics (PK) of 90Y-hPAM4 as determined by pre-therapy administration of 111In-hPAM4, the assessment of the antigenicity of 90Y-hPAM4, as determined by development of human anti-humanized antibodies (HAHA), and to obtain preliminary information on the efficacy of single dose 90Y-hPAM4 in this patient population.


Inclusion Criteria: - Male or female patients, >18 years of age, who are able to understand and give written informed consent. - Histologically or cytologically confirmed, Stage III or IV pancreatic adenocarcinoma. - Patients with Stage III (locally advanced) disease must have documented progression after failing primary therapy - Patients with Stage IV (metastatic) disease must not have received more than one chemotherapy regimen. - Measurable disease by CT, with at least on lesion >1.5 cm in one dimension. - Karnofsky performance status > 70 % (Appendix A). - Expected survival > three months. - At least 4 weeks beyond chemotherapy, radiotherapy, major surgery, other experimental treatments, and recovered from all acute toxicities. - At least 2 weeks beyond corticosteroids, except low doses (i.e., 20 mg/day of prednisone or equivalent) to treat nausea or other illness such as rheumatoid arthritis - Adequate hematology without ongoing transfusional support (hemoglobin > 10 g/dL, ANC > 1,500 per mm3, platelets > 150,000 per mm3) - Adequate renal and hepatic function (creatinine and bilirubin ≤ 1.5 X IULN, AST and ALT ≤ 2.0 X IULN) - Otherwise, all toxicity at study entry <Grade 1 by NCI CTC v3.0. Exclusion Criteria: - Women who are pregnant or lactating. - Women of childbearing potential and fertile men unwilling to use effective contraception during study until conclusion of 12-week post-treatment evaluation period. - Known metastatic disease to the central nervous system. - Presence of bulky disease (defined as any single mass >10 cm in its greatest dimension) - Patients with >Grade 2 anorexia, nausea or vomiting, and/or signs of intestinal obstruction. - Prior treatment with nitrosureas, actinomycin-D, radioimmunotherapy or other antibody-based therapies (murine, chimeric, humanized or human) Prior radiation dose >3,000 cGy to the liver, >2,000 cGy to lungs and kidneys or prior external beam irradiation to a field that includes more than 30% of the red marrow. - Patients with non-melanoma skin cancer or carcinoma in situ of the cervix are not excluded, but patients with other prior malignancies must have had at least a 5- year disease free interval. - Patients known to be HIV positive, hepatitis B positive, or hepatitis C positive. - Known history of active coronary artery disease, unstable angina, myocardial infarction, or congestive heart failure present within 6 months or cardiac arrhythmia requiring anti-arrhythmia therapy. - Known history of active COPD, or other moderate-to-severe respiratory illness present within 6 months. - Known autoimmune disease or presence of autoimmune phenomena (except rheumatoid arthritis requiring only low dose maintenance corticosteroids). - Infection requiring intravenous antibiotic use within 1 week. - Other concurrent medical or psychiatric conditions that, in the Investigator's opinion, may be likely to confound study interpretation

Study is Available At:

Original ID:




Secondary ID:

Study Acronym:

Brief Title:

Safety and Efficacy Study of 90Y-hPAM4 at Different Doses

Official Title:

A Phase I, Dose-Escalating Study to Investigate the Safety, Tolerability, Pharmacokinetics and Dosimetry of a Single Dose of 90YHumanized PAM4 IgG in Patients With Locally Advanced/Metastatic Pancreatic Cancer

Overall Status:


Study Phase:

Phase 1/Phase 2



Minimum Age:

18 Years

Maximum Age:


Quick Facts

Healthy Volunteers
Oversight Has DMC
Study Is FDA Regulated
Study Is Section 801
Has Expanded Access

Study Source:

Immunomedics, Inc.

Oversight Authority:

United States: Food and Drug Administration

Reasons Why Stopped:

Study Type:


Study Design:

Allocation: Non-Randomized, Endpoint Classificati

Number of Arms:


Number of Groups:


Total Enrollment:


Enrollment Type:


Overall Contact Information

Official Name:William Wegener, MD, PhD
Study Chair
Immunomedics, Inc.

Study Dates

Start Date:August 2004
Completion Date:October 2007
Completion Type:Actual
Primary Completion Date:October 2007
Primary Completion Type:Actual
Verification Date:January 2008
Last Changed Date:January 8, 2008
First Received Date:January 8, 2008

Study Outcomes

Outcome Type:Primary Outcome
Measure:safety MTD
Time Frame:over the first 12 weeks, then over 2 years
Safety Issues:True
Outcome Type:Secondary Outcome
Measure:targeting, biodistribution, organ dosimetry
Time Frame:first 2 weeks
Safety Issues:True
Outcome Type:Secondary Outcome
Measure:pharmacokinetics (PK), antigenicity,
Time Frame:first 12 weeks
Safety Issues:True
Outcome Type:Secondary Outcome
Time Frame:over first 12 weeks, then over 2 years
Safety Issues:False

Study Interventions

Intervention Type:Biological
Description:Single dose of 90Y-hPAM4 will be given and all patients will be followed for 12 weeks.
Arm Name:Multi Dose levels
Other Name:90Y-hPAM4

Study Arms

Study Arm Type:Experimental
Arm Name:Multi Dose levels
Description:different doses of 90YhPAM4 will be given only once.

Study Agencies

Agency Class:Industry
Agency Type:Lead Sponsor
Agency Name:Immunomedics, Inc.

Sample and Retention Information

There are no available Sample and Retention Information

Study References

Reference Type:Reference
Citation:Gold DV, Karanjawala Z, Modrak DE, Goldenberg DM, Hruban RH. PAM4-Reactive MUC1 Is a Biomarker for Early Pancreatic Adenocarcinoma. Clin Cancer Res. 2007 Dec 15;13(24):7380-7.
Reference Type:Reference
Citation:Modrak DE, Gold DV, Goldenberg DM. Sphingolipid targets in cancer therapy. Mol Cancer Ther. 2006 Feb;5(2):200-8. Review.
Reference Type:Reference
Citation:Gold DV, Modrak DE, Ying Z, Cardillo TM, Sharkey RM, Goldenberg DM. New MUC1 serum immunoassay differentiates pancreatic cancer from pancreatitis. J Clin Oncol. 2006 Jan 10;24(2):252-8. Epub 2005 Dec 12.
Reference Type:Reference
Citation:Modrak DE, Karacay H, Cardillo TM, Newsome G, Goldenberg DM, Gold DV. Identification of a Mu-9 (anti-colon-specific antigen-p)-reactive peptide having homology to CA125 (MUC16). Int J Oncol. 2005 Jun;26(6):1591-6.
Reference Type:Reference
Citation:Modrak DE, Cardillo TM, Newsome GA, Goldenberg DM, Gold DV. Synergistic interaction between sphingomyelin and gemcitabine potentiates ceramide-mediated apoptosis in pancreatic cancer. Cancer Res. 2004 Nov 15;64(22):8405-10.
Reference Type:Reference
Citation:Gold DV, Modrak DE, Schutsky K, Cardillo TM. Combined 90Yttrium-DOTA-labeled PAM4 antibody radioimmunotherapy and gemcitabine radiosensitization for the treatment of a human pancreatic cancer xenograft. Int J Cancer. 2004 Apr 20;109(4):618-26.
Reference Type:Reference
Citation:Gold DV, Schutsky K, Modrak D, Cardillo TM. Low-dose radioimmunotherapy ((90)Y-PAM4) combined with gemcitabine for the treatment of experimental pancreatic cancer. Clin Cancer Res. 2003 Sep 1;9(10 Pt 2):3929S-37S.
Reference Type:Reference
Citation:Modrak DE, Gold DV, Goldenberg DM, Blumenthal RD. Colonic tumor CEA, CSAp and MUC-1 expression following radioimmunotherapy or chemotherapy. Tumour Biol. 2003 Jan-Feb;24(1):32-9.
Reference Type:Reference
Citation:Reddy PK, Gold DV, Cardillo TM, Goldenberg DM, Li H, Burton JD. Interferon-gamma upregulates MUC1 expression in haematopoietic and epithelial cancer cell lines, an effect associated with MUC1 mRNA induction. Eur J Cancer. 2003 Feb;39(3):397-404.
Reference Type:Reference
Citation:Cardillo TM, Blumenthal R, Ying Z, Gold DV. Combined gemcitabine and radioimmunotherapy for the treatment of pancreatic cancer. Int J Cancer. 2002 Jan 20;97(3):386-92.
Reference Type:Reference
Citation:Cardillo TM, Ying Z, Gold DV. Therapeutic advantage of (90)yttrium- versus (131)iodine-labeled PAM4 antibody in experimental pancreatic cancer. Clin Cancer Res. 2001 Oct;7(10):3186-92.
Reference Type:Reference
Citation:Gold DV, Cardillo T, Goldenberg DM, Sharkey RM. Localization of pancreatic cancer with radiolabeled monoclonal antibody PAM4. Crit Rev Oncol Hematol. 2001 Jul-Aug;39(1-2):147-54.
Reference Type:Reference
Citation:Gold DV, Cardillo T, Vardi Y, Blumenthal R. Radioimmunotherapy of experimental pancreatic cancer with 131I-labeled monoclonal antibody PAM4. Int J Cancer. 1997 May 16;71(4):660-7.
Reference Type:Reference
Citation:Mariani G, Molea N, Bacciardi D, Boggi U, Fornaciari G, Campani D, Salvadori PA, Giulianotti PC, Mosca F, Gold DV, et al. Initial tumor targeting, biodistribution, and pharmacokinetic evaluation of the monoclonal antibody PAM4 in patients with pancreatic cancer. Cancer Res. 1995 Dec 1;55(23 Suppl):5911s-5915s.
Reference Type:Reference
Citation:Alisauskus R, Wong GY, Gold DV. Initial studies of monoclonal antibody PAM4 targeting to xenografted orthotopic pancreatic cancer. Cancer Res. 1995 Dec 1;55(23 Suppl):5743s-5748s.
Reference Type:Reference
Citation:Gold DV, Alisauskas R, Sharkey RM. Targeting of xenografted pancreatic cancer with a new monoclonal antibody, PAM4. Cancer Res. 1995 Mar 1;55(5):1105-10.
Reference Type:Reference
Citation:Gold DV, Lew K, Maliniak R, Hernandez M, Cardillo T. Characterization of monoclonal antibody PAM4 reactive with a pancreatic cancer mucin. Int J Cancer. 1994 Apr 15;57(2):204-10.

Data Source:

Date Processed: March 30, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

This study is not currently recruiting Study Participants. The form below is not enabled.